ClinicalTrials.gg
CompletedNCT01482910Updated Nov 4, 2016Results posted

VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

A Phase 3 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) and Visudyne in Macular Degeneration, sponsored by Bayer. Completed at 14 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-11-04.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
14th of 66
304 · median 55
Started
2011
the only one that year
Phase 3
18 of 66
1 open now
Registered
7th of 66
by date
Lead sponsor
8 of 66
Bayer

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 14th largest by enrollment, is the only one that started in 2011, is one of 18 in phase 3, and was the 7th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of intravitreally (IVT), i.e. directly into the eye administered VEGF Trap-Eye compared with photodynamic therapy (PDT) on visual function in Chinese subjects with age-related neovascular or "wet" age-related macular degeneration.

Subjects will be randomized in a 3:1 ratio to either receive VEGF Trap-Eye or PDT. Both treatment groups will receive the other treatment as a sham procedure.

Read the detailed description

Adverse events collection will be covered in Adverse Events section.

03

Conditions studied

  • Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated form
  • Men and women ≥ 50 years of age.
  • Active predominantly classic subfoveal choroidal neovascularization (CNV) lesions secondary to wAMD (wet Age-Related Macular Degeneration)
  • BCVA (best corrected visual acuity) of 20/40 to 20/320 in the study eye

Exclusion criteria

Exclusion Criteria:

  • Only one functional eye
  • Presence of CNV with an origin other than wAMD
  • Any prior ocular or systemic treatment or surgery for wAMD, except dietary supplements or vitamins
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.

    Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

  • Active comparator
    PDT treatments

    Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.

    Drug: Visudyne

Interventions

  • Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.

  • Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)

    Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.

    Time frame: Baseline and at week 28

Secondary outcomes

  1. Percentage of Participants Who Lost Fewer Than 15 Letters at Week 28 - LOCF

    Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.

    Time frame: At week 28

07

Results

Posted Mar 13, 2015

Participant flow

Participant flow — Overall Study
MilestoneAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)PDT Treatments
Started22876
Completed week 2821671
Completed21367
Not completed159
Withdrew: Adverse event65
Withdrew: Lost to follow-up01
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject72
Withdrew: Death10

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.

Time frame:
Baseline and at week 28
Reported as:
Mean · Letters correctly read
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)
Letters correctly readAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)PDT Treatments
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)14.0 ± 12.13.9 ± 14.6
Statistical analysis
  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) vs PDT Treatments · ANCOVA · p = <0.0001 (Hierarchical testing procedure was used in the order of pre-defined fixed sequence (primary endpoint first, then confirmatory secondary efficacy point next). A two-sided significance level of 0.05 was used.) · Mean difference (final values): 10.1 · 95% CI 6.8 to 13.4Least square mean difference (EYLEA-PDT) was estimated from ANCOVA, where a positive value is in favor of EYLEA.
SecondaryPercentage of Participants Who Lost Fewer Than 15 Letters at Week 28 - LOCF

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.

Time frame:
At week 28
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost Fewer Than 15 Letters at Week 28 - LOCF
Percentage of participantsAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)PDT Treatments
Percentage of Participants Who Lost Fewer Than 15 Letters at Week 28 - LOCF98.792.1
Statistical analysis
  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) vs PDT Treatments · Cochran-Mantel-Haenszel · p = 0.0359 (Hierarchical testing procedure was used in the order of pre-defined fixed sequence (primary endpoint first, then confirmatory secondary efficacy point next). A two-sided significance level of 0.05 was used.) · Risk difference (rd): 6.6 · 95% CI 0.4 to 12.9Proportion difference (EYLEA-PDT) was estimated from CMH, where a positive value is in favor of EYLEA.

Adverse events

Collected over From the first study drug injection until 30 days after the last study drug injection at the latest up to week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept Injection, up to Week 28—13/228 (5.7%)77/228 (33.8%)
PDT Treatments, up to Week 28—4/76 (5.3%)33/76 (43.4%)
Aflibercept Injection, From Week 28 to Week 52—5/216 (2.3%)18/216 (8.3%)
PDT Then Aflibercept Injection, From Week 28 to Week 52—3/71 (4.2%)9/71 (12.7%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventAflibercept Injection, up to Week 28PDT Treatments, up to Week 28Aflibercept Injection, From Week 28 to Week 52PDT Then Aflibercept Injection, From Week 28 to Week 52
Visual acuity reducedEye disorders2/2283/760/2160/71
Acute myocardial infarctionCardiac disorders0/2280/760/2161/71
CataractEye disorders0/2280/760/2161/71
Cerebral infarctionNervous system disorders1/2280/760/2161/71
Diabetes mellitusMetabolism and nutrition disorders0/2281/760/2160/71
Sudden hearing lossEar and labyrinth disorders0/2280/761/2160/71
Vitreous haemorrhageEye disorders0/2280/761/2160/71
GastritisGastrointestinal disorders0/2280/761/2160/71
Cerebral ischaemiaNervous system disorders0/2280/761/2160/71
HypertensionVascular disorders0/2280/761/2160/71
Most frequent other events
Most frequent other events
EventAflibercept Injection, up to Week 28PDT Treatments, up to Week 28Aflibercept Injection, From Week 28 to Week 52PDT Then Aflibercept Injection, From Week 28 to Week 52
Visual acuity reducedEye disorders16/22811/766/2165/71
Macular fibrosisEye disorders27/2288/766/2160/71
Retinal pigment epitheliopathyEye disorders12/2288/766/2161/71
Conjunctival haemorrhageEye disorders14/2284/7613/2164/71
Retinal haemorrhageEye disorders9/2284/760/2160/71
Subretinal fluidEye disorders2/2284/762/2161/71
Upper respiratory tract infectionInfections and infestations10/2284/766/2160/71
Intraocular pressure increasedInvestigations12/2282/762/2161/71

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)PDT TreatmentsTotal
Mean65.1 ± 8.864.9 ± 8.565.1 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)PDT TreatmentsTotal
Female8622108
Male14254196
08

Study locations

14 sites
  • Guangzhou, Guangdong 510060, China
  • Changsha, Hunan 410011, China
  • Xi'an, Shaanxi 710032, China
  • Qingdao, Shandong, China
  • Chengdu, Sichuan 610041, China
  • Hangzhou, Zhejiang 310003, China
  • Hangzhou, Zhejiang 310009, China
  • Wenzhou, Zhejiang, China
  • Beijing, 100044, China
  • Beijing, 100083, China
  • Beijing, 100730, China
  • Beijing, 2000080, China
  • Shanghai, China
  • Tianjin, 300384, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Mar 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2011
First posted
Dec 1, 2011
Start
Dec 2011
Primary completionActual
Mar 2014
CompletionActual
Aug 2014
Results first posted
Mar 13, 2015
Last update
Nov 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01482910
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 1, 2011
Start date
Dec 2011
Primary completion
Mar 2014
Completion
Aug 2014
Results posted
Mar 13, 2015
Last update
Nov 4, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion